In vivo protection by broadly neutralizing HIV antibodies.
Passive immunization studies, including a recent one by Pegu et al., have repeatedly shown that HIV-specific broadly neutralizing antibodies (bnAbs) protect rhesus macaques from HIV acquisition. In vitro neutralization potency and in vivo protection correlate very strongly, supporting the quest for an HIV vaccine that induces potent bnAbs.